3106269131

Kelly, E.J., Nace, R., Barber, G.N., and Russell, S.J. (2010). Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting. J. Virol. 84, 1550-1562.

Kopeky, S.A., Wlillingham, M.C., and Lyles, D.S. (2001). Matrix Protein and Another Viral Component Contribute to Induction of Apoptosis in Cells Infected with Vesicular Stomatitis Virus. J. Virol. 75 12169-12181.

Le Boeuf, F., Diallo, J.-S., McCart, J.A., Thome, S., Falls, T., Stanford, M., Kanji, F., Auer, R., Brown, C.W., Lichty, B.D., et al. (2010). Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Mol. Ther. 18, 888-895.

Lemay, G. (2012). Apprivoiser nos ennemis pour en faire des allies: la « virotherapie » anticancćreuse. Med Sci (Paris) 28, 339-340.

Letchworth, G.J., Rodriguez, L.L., and Del Cbarrera, J. (1999). Vesicular Stomatitis. The Veterinary Journal 157, 239-260.

Libersou, S., Albertini, A.A.V., Ouldali, M., Maury, V., Maheu, C., Raux, H., de Haas, F., Roche, S., Gaudin, Y., and Lepault, J. (2010). Distinct structural rearrangements of the VSV glycoprotein drive membranę fusion The Journal of Celi Biology 191, 199-210.

Lichty, B.D., Power, A.T., Stojdl, D.F, and Bell, J.C. (2004). Vesicular stomatitis virus: re-inventing the bullet. TRENDS in Molecular Medecine 10, 211-217.

Lyles, D.S, McKenzie, M.O, Kaptur, P.E., Grant, K.W., and Jerome, W.G. (1996). Complementation of M Gene Mutants of Vesicular Stomatitis Virus by Plasraid-Derived M Protein Converts Spherical Extracellular Particles into Native Bullet Shapes. Virology 217, 76-87.

McCreedy, B.J.J., and Lyles, D.S. (1989). Distribution of M protein and nucleocapsid protein of vesicular stomatitis virus in infected celi plasma membranes. Virus Res. 14, 189-205.

Melki, R., Gaudin, Y., and Blondel, D. (1994). Interaction between Tubulin and the Viral Matrix Protein of Vesicular Stomatitis Virus: Possible Implications in the Viral Cytopathic Effect. Virology 202, 339-347.

Msaouel, P., Dispenzieri, A., and Galanis, E (2009) Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr. Opin. Mol. Ther 77,43-53.